1. better probing for hypomania (thus BD-II), overcoming the misdiagnoses of structured interviews by using semi-structured interviews carried out by clinicians, which assess all past hypomanic symptoms, especially overactivity, and bypass the stem, and skip out the question on mood change of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) Structured Clinical Interview for DSM-IV (SCID), a cause of missed BD-II diagnoses;
2. shorter, validated minimum duration of hypomania (1 to 3 days), as the 4-day DSM-IV minimum duration is only consensus-based;
3. inclusion of MDD with bipolar features not otherwise specified, such as bipolar family history, young age-at-onset, many recurrences, mixed depression (that is, the cooccurrence of depression and subthreshold hypomania); and 4. while SCID focuses mainly on the impairment (nonmarked) for diagnosing hypomania; most hypomania have superior functioning (reviewed by Benazzi 2 ).
The same DSM-IV-TR reports in the text that hypomania may have "increase in efficiency, accomplishments, or creativity," compared with the usual behaviour, or some functional impairment. Hecker 3 reported that most outpatient hypomanias have superior functioning, while Kraepelin, 4 studying inpatients, reported more on the impairment of hypomania. So, a syndrome that does not meet DSM-IV criteria for a disorder (that is, distress and impairment) should still be considered a disorder? By itself, hypomania is often a pleasant period of improved functioning. However, BD-II is mainly a depressive disorder, 2 and hypomania occupies a minority of the period of illness. 2 Compared with MDD, BD-II is more severe (for example, more recurrences, comorbidity, suicidality, and unstable course), which makes detection of hypomania important for treatment and outcome (clinical validity). 2 Beyond BD-II, MDD with bipolar features has been included in the bipolar spectrum. Its clinical utility (and need to detection) has been preliminary shown by finding that in bipolar mixed depression (mixed depression is not uncommon in MDD, too) the concurrent subsyndromal hypomanic symptoms can be worsened by antidepressants (lower response rate, more switching rate). 2,5 I fully share the view by Dr Patten and Dr Paris that the best test of the bipolar spectrum is its clinical validity. Up to now, many bipolar spectrum disorders have yet to show clear evidence of clinical validity (apart from BD-II). I would support research in this area, more to assess clinical utility than diagnostic validity (given the unknown biological underpinnings of BDs, the current validators are only a questioned proxy of validation).
Franco Benazzi, MD, DTMH, PhD
Forli, Italy
REPLY

Re: The Bipolar Spectrum-A Bridge Too Far?
Dear Editor: Dr Benazzi's letter in response to our review article 1 reiterates several arguments that have been presented in prior reviews of the bipolar spectrum concept. 2, 3 These ideas lead to interesting hypotheses about the potential value of revised diagnostic definitions and also lead to hypotheses about the potential efficacy of bipolar treatments for various clinical problems. Our motivation in reviewing this literature again was not to assess whether such conjecture can reasonably be entertained, but rather to determine whether there is actual high-quality evidence supporting diagnostic and therapeutic changes from the perspective of evidence-based practice.
Our approach to this problem is one that is considered essential in much of medicine but has not yet been adopted in the bipolar spectrum literature. The approach involved the use of a clearly described search strategy and systematic assessment of the quality of studies uncovered in the literature search. These approaches provide protection against bias that may otherwise distort more narrative approaches to the summarization of evidence.
We adopted a quality assessment protocol restricting inclusion to studies that were methodologically capable of providing high-level evidence in support of altered clinical practice. Consistent with current standards of evidence-based medicine, we took this to mean evidence deriving from randomized controlled trials or high-quality prospective cohort studies. The main finding of our review is that such evidence does not exist. We seem to be in agreement with Dr Benazzi on this point.
Because of the lack of suitable studies, our review could not progress to meta-analysis or sensitivity analysis in the way that many systematic reviews do. It is for this reason that we devoted some space in the article to describing conceptual issues that have emerged in the bipolar spectrum literature. Doing so may have created the impression that we were interested in engaging in a debate about which disorders are most common in clinical practice, or about the interpretation of case-series and descriptive epidemiologic data, or even of revisiting the writings of Kraepelin. On the contrary, our goal was to seek out high-level evidence that would justify modification of evidence-based practice. Notably, we considered bipolar II disorder to be a component of the current nosology and we did not consider this to be an example of an expanded bipolar spectrum. Once again, our review did not identify any studies capable of providing the sort of evidence that we sought. An exception, which is mentioned in the paper, is lithium responsiveness in highly recurrent depressive disorders. This does provide evidence of clinical utility if lithium responsiveness is taken to be a key feature of bipolarity.
